AJ2-30

• Description:

  AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits endolysosomal TLR7-9-mediated mTOR activation. AJ2-30 blocks endogenous NOD signaling. AJ2-30 can be used in inflammation studies[1][2].

• UNSPSC:

  12352005

• Target:

  MTOR; NOD-like Receptor (NLR) ; Oligopeptide Cotransporter

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/aj2-30.html

• Concentration:

  10mM

• Purity:

  99.72

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CCN1C2=C(C=CC=C2)C3=CC(CNC4=NC5=C(N4C)C=CC=C5)=CC=C31

• Molecular Formula:

  C23H22N4

• Molecular Weight:

  354.45

• References & Citations:

  [1]Daniel Lazar, et al. Small molecule inhibitors of scl15a4 with anti-inflammatory activity. Patent. WO2021174023.|[2]Chiu TY, et al. Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. Nat Chem Biol. 2024 Aug;20 (8) :1000-1011.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2700322-79-6]